Fas ligand overexpression on allograft endothelium inhibits inflammatory cell infiltration and transplant-associated intimal hyperplasia1

Journal of Immunology

Volumn 166, Issue 11, 2001, Pages 6964-6971

  Sata, Masataka ^a,b   Lou, Zhengyu ^a   Walsh, Kenneth ^a,b,c,d  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TOKYO   (Japan)

^c TUFTS UNIVERSITY   (United States)

^d ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND;

ADENOVIRUS; ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL INFILTRATION; CELL SPECIFICITY; CELL SURFACE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; ENDOTHELIUM CELL; GENE OVEREXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; INFLAMMATORY CELL; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; RODENT; SURVIVAL TIME; T LYMPHOCYTE; TRANSPLANTATION; VASCULAR DISEASE;

EID: 0343773374     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.11.6964     Document Type: Article

References (63)

1. Billingham, M. E. 1987. Cardiac transplant atherosclerosis. Transplant. Proc. 19:19.
2. Hruban, R. H., W. B. Beschorner, W. A. Baumgartner, S. M. Augustine, H. Ren, B. A. Reitz, and G. M. Hutchins. 1990. Accelerated arteriosclerosis in heart transplant recipients is associated with a T-lymphocyte-mediated endothelialitis. Am. J. Pathol. 137:871.
3. Russel, P. S., C. M. Chase, H. J. Winn, and R. B. Colvin. 1994. Coronary atherosclerosis in transplanted mouse hearts. Am. J. Pathol. 144:260.
4. Ross, R. 1996. Genetically modified mice as models of transplant atherosclerosis. Nat. Med. 2:527.
5. Isik, F. F., T. O. McDonald, M. Ferguson, E. Yamanaka, and D. Gordon. 1992. Transplant arteriosclerosis in a rat aortic model. Am. J. Pathol. 141:1139.
6. Nagata, S., and P. Golstein. 1995. The Fas death factor. Science 267:1449.
7. Griffith, T. S., T. Brunner, S. M. Fletcher, D. R. Green, and T. A. Ferguson. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270: 1189.
8. Hahne, M., D. Rimoldi, M. Schröter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, et al. 1996. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363.
9. Strand, S., W. J. Hofman, H. Hug, M. Müller, G. Otto, D. Strand, S. M. Mariani, W. Stremmel, P. H. Krammer, and P. R. Galle. 1996. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand expressing tumor cells: a mechanism of immune evasion? Nat. Med. 2:1361.
10. French, L. E., M. Hahne, I. Viard, G. Radlgruber, R. Zanone, K. Becker, C. Muller, and J. Tschopp. 1996. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J. Cell Biol. 133:335.
11. Saas, P., P. R. Walker, M. Hahne, A.-L. Quiquerez, V. Schnuringer, G. Perrin, L. French, E. G. Van Meir, N. Tribolet, J. Tschopp, and P.-Y. Dietrich, 1997. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J. Clin. Invest. 99:1173.
12. Stuart, P. M., T. S. Griffith, N. Usui, J. Pepose, X. Yu, and T. A. Ferguson. 1997. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J. Clin. Invest. 99:396.
13. Bellgrau, D., D. Gold, H. Selawry, J. Moore, A. Franzusoff, and R. C. Duke. 1995. A role of CD95 ligand in preventing graft rejection. Nature 377:630.
14. Seino, K., N. Kayagaki, K. Okumura, and H. Yagita. 1997. Antitumor effect of locally produced CD95 ligand. Nat. Med. 3:165.
15. Lau, H. T., M. Yu, A. Fontana, and C. J. Stoeckert. 1996. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 273:109.
16. Muruve, D., A. Nicolson, R. Manfro, T. Strom, V. Sukhatme, and T. Libermann. 1997. Adenovirus mediated expression of Fas ligand induces hepatic apoptosis after systemic administration and apoptosis of ex vivo infected pancreatic islet allografts and isografts. Hum. Gene Ther. 8:955.
17. Kang, S. M., D. B. Schneider, Z. Lin, D. Hanahan, D. A. Dichek, P. G. Stock, and S. Baekkeskov. 1997. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med. 3:738.
18. Allison, J., H. M. Georgiou, A. Strasser, and D. L. Vaux. 1997. Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografis. Proc. Natl. Acad. Sci. USA 94:3943.
19. Swenson, K. M., B. Ke, T. Wang, J. S. Markowitz, M. A. Maggard, G. S. Spear, D. K. Imagawa, J. A. Goss, R. W. Busuttil, and P. Seu. 1998. Fas ligand gene transfer to renal allografts in rats: effects on allograft survival. Transplantation 65:155.
20. Yagita, H., K. Seino, N. Kayagaki, and K. Okumura. 1996. CD95 ligand in graft rejection. Nature 379:682.
21. Kang, S. M., A. Hofmann, D. Le, M. L. Springer, P. G. Stock, and H. M. Blau. 1997. Immune response and myoblasts that express Fas ligand. Science 278: 1322.
22. Miwa, K., M. Asano, R. Horai, Y. Iwakura, S. Nagata, and T. Suda. 1998. Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand. Nat. Med. 4:1287.
23. Richardson, B. C., N. D. Lalwani, K. J. Johnson, and R. M. Marks. 1994. Fas ligation triggers apoptosis in macrophages but not endothelial cells. Eur. J. Immunol. 24:2640.
24. Sata, M., and K. Walsh. 1998. TNFα regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat. Med. 4:415.
25. Tran, T. H., S. Grey, J. Anrather, F. Steinhauslin, F. H. Bach, and H. Winkler. 1998, Regulated and endothelial cell-specific expression of Fas ligand: an in vitro model for a strategy aiming at inhibiting xenograft rejection. Transplantation 66:1126.
26. Sata, M., T. Suhara, and K. Walsh. 2000. Vascular endothelial cells and smooth muscle cells differ in expression of Fas and Fas ligand and in sensitivity to Fas ligand induced cell death: implications for vascular disease and therapy. Arterioscler. Thromb. Vasc. Biol. 20:309.
27. Sata, M., and K. Walsh. 1998. Oxidized LDL activates Fas-mediated endothelial cell apoptosis. J. Clin. Invest. 102:1682.
28. Sata, M., and K. Walsh. 1998. Endothelial cell apoptosis induced by oxidized LDL is associated with the downregulation of the cellular caspase inhibitor FLIP. J. Biol. Chem. 273:33103.
29. Sata, M., H. Perlman, D. A. Muruve, M. Silver, M. Ikebe, T. A. Libermann, P. Oettgen, and K. Walsh. 1998. Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response. Proc. Natl. Acad. Sci. USA 95:1213.
30. Matzinger, P. 1991. The JAM test: a simple assay for DNA fragmentation and cell death. J. Immunol. Methods 145:185.
31. McGahon, A. J., S. J. Martin, R. P. Bissonnette, A. Mahboubi, Y. Shi, R. J. Mogil, W. K. Nishioka, and D. R. Green. 1995. The end of the cell line: methods for the study of apoptosis in vitro. In Cell death. Vol. 46. L. M. Schwartz and B. A. Osborne, eds. Academic Press, San Diego, CA, p. 153.
32. Stokes, T. A., M. Rymaszewski, P. L. Arscott, S. H. Wang, J. D. Bretz, J. Bartron, and J. R. J. Baker. 1998. Constitutive expression of FasL in thyrocytes. Science 279:2015.a.
33. Chen, J.-J., Y. Sun, and G. J. Nabel. 1998. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 282:1714.
34. Waltenberger, J., M. L. Akyurek, M. Aurivillius, A. Wanders, E. Larsson, B. Fellstrom, and K. Funa. 1996. Ischemia-induced transplant arteriosclerosis in the rat: induction of peptide growth factor expression. Arterioscler. Thromb. Vasc. Biol. 16:1516.
35. Meiser, B. M., M. E. Billingham, and R. E. Morris. 1991. Effects of cyclosporin. FK506, and rapumycin on graft-vessel disease. Lancet 338:1297.
36. Calne, R. Y., D. S. J. Collier, S. Lim, S. G. Pollard, A. Samaan, D. J. G. White, and S. Thiru. 1989. Rapamycin for immunosuppression in organ allografting. Lancet 8656:227.
37. Mennander, A., S. Tiisala, T. Paavonen, J. Halttunen, and P. Hayry. 1991. Chronic rejection of rat aortic allograft: administration of cyclosporin induces accelerated allograft arteriosclerosis. Transplants. Int. 4:173.
38. Sommer, B. G., J. T. Innes, R. M. Whitehurst, H. M. Sharma, and R. M. Ferguson. 1985. Cyclosporine-associated renal arteriopathy resulting in loss of allograft function. Am. J. Surg. 149:759.
39. Demetris, A. J., S. Lasky, D. H. Theil, T. E. Starzl, and A. Dekker. 1985. Pathology of hepatic transplantation: a review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid combination. Am. J. Pathol. 118: 151.
40. Russell, P. S., C. M. Chase, and R. B. Colvin. 1997. Alloantibody- and T cell-mediated immunity in the pathogenesis of transplant arteriosclerosis: lack of progression to sclerotic lesions in B cell-deficient mice. Transplantation 64:1531.
41. Russell, P. S., C. M. Chase, H. J. Winn, and R. B. Colvin. 1994. Coronary atherosclerosis in transplanted mouse hearts. II. Importance of humoral immunity. J. Immunol. 152:5135.
42. Arai, H., S. Y. Chan, D. K. Bishop, and G. J. Nabel. 1997. Inhibition of the alloantibody response by CD95 ligand. Nat. Med. 3:843.
43. Newman, K. D., P. F. Dunn, J. W. Owens, A. H. Schulick, R. Virmani, G. Sukhova, P. Libby, and D. A. Dichek. 1995. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J. Clin. Invest. 96:2955.
44. Larsen, C. P., E. T. Elwood, D. Z. Alexander, S. C. Ritchie, R. Hendrix, C. Tucker-Burden, H. R. Cho, A. Aruffo, D. Hollenbaugh, P. S. Linsley, et al. 1996. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381:414.
45. Allan, J. S., J. K. Choo, L. Vesga, J. S. Arn, M. R. Pins, D. H. Sachs, and J. C. Madsen. 1997. Cardiac allograft vasculopathy is abrogated by anti-CD8 monoclonal antibody therapy. Ann. Thorac. Surg. 64:1019.
46. Chow, L. H., S. Huh, J. Jiang, R. Zhong, and J. G. Pickering. 1996. Intimal thickening develops without humoral immunity in a mouse aortic allograft model of chronic vascular rejection. Circulation 94:3079.
47. Shi, C., W.-S. Lee, Q. He, D. Zhang, D. L. J. Fletcher, J. B. Newell, and E. Haber. 1996. Immunologic basis of transplant-associated arteriosclerosis. Proc. Natl. Acad. Sci. USA 93:4051.
48. Dong, C., D. Redenbach, S. Wood, B. Battistini, J. E. Wilson, and B. M. McManus. 1996. The pathogenesis of cardiac allograft vasculopathy. Curr. Opin. Cardiol. 11:183.
49. Okada, K., Y. Nishida, H. Murakami, I. Sugimoto, H. Kosaka, H. Morita, C. Yamashita, and M. Okada. 1998. Role of endogenous endothelin in the development of graft arteriosclerosis in rat cardiac allografts: antiproliferative effects of bosentan, a nonselective endothelin receptor antagonist. Circulation 97: 2346.
50. Furukawa, Y., A. Matsumori, T. Hirozane, and S. Sasayama. 1996. Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model: a comparative study with captopril. Circulation 93:333.
51. Cao, W., P. Mohacsi, R. Shorthouse, R. Pratt, and R. Morris. 1995. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis: inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation 59:390.
52. Morris, R. E., W. Cao, X. Huang, C. R. Gregory, M. E. Billingham, R. Rowan, and R. A. Shorthouse. 1995. Rapamycine (Sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses narrowing in arterial allografts and in balloon-injured carotid arteries: evidence that rapamycin antagonizes growth factor action on immune and nonimmune cells. Transplant. Proc. 27:430.
53. Poston, R. S., M. Billingham, G. Hoyt, J. Pollard, R. Shorthouse, R. E. Morris, and R. C. Robbins. 1999. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Circulation 100:67.
54. Suzuki, J.-I., M. Isobe, R. Morishita, M. Aoki, S. Horie, Y. Okuho, Y. Kaneda, Y. Sawa, H. Matsuda, T. Ogihara, and M. Sekiguchi. 1997. Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide. Nat. Med. 3:900.
55. Rekhter, M. D., N. Shah, R. D. Simari, C. Work, J.-S. Kim, G. J. Nabel, E. G. Nabel, and D. Gordon. 1998. Graft permeabilization facilitates gene therapy of transplant arteriosclerosis in a rabbit model. Circulation 98:1335.
56. Luo, Z., M. Sata, T. Nguyen, J. M. Kaplan, G. Y. Akita, and K. Walsh. 1999. Adenovirus-mediated delivery of Fas ligand inhibits intimal hyperplasia after balloon injury in immunologically primed animals. Circulation 99:1776.
57. Wilbanks, G. A., M. Mammolenti, and J. W. Streilein. 1992. Studies on the induction of anterior chamber-associated immune deviation (ACAID). III. Induction of ACAID depends upon intraocular transforming growth factor-β. Eur. J. Immunol. 22:165.
58. Gresham, H. D., C. J. Ray, and F. X. O'Sullivan. 1991. Defective neutrophil function in the autoimmune mouse strain MRL/lpr: potential role of transforming growth factor-β. J. Immunol. 146:3911.
59. Horvath, L. Z., H. Friess, M. Schilling, B. Borisch, J. Deflorin, L. I. Gold, M. Kore, and M. W. Buchler. 1996. Altered expression of transforming growth factor-β S in chronic renal rejection. Kidney Int. 50:489.
60. Nikol, S., J. M. Isner, J. G. Pickering, M. Kearney, O. Leclerc, and L. Weir. 1992. Expression of transforming growth factor β1 is increased in human vascular restenosis. J. Clin. Invest. 90:1582.
61. Madri, J. A., M. A. Reidy, O. Kocher, and L. Bell. 1989. Endothelial cell behavior after denudation injury is modulated by transforming growth factor-β1 and fibronectin. Lab. Invent. 60:755.
62. Majesky, M. W., V. Lindner, D. R. Twardzik, S. M. Schwartz, and M. A. Reidy. 1991. Production of transforming growth factor β1 during repair of arterial injury. J. Clin. Invest. 88:904.
63. O'Connell, J., A. Houston, M. W. Bennett, G. C. O'Sullivan, and F. Shanahan. 2001. Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat. Med. 7:271.